Summary The matrix metalloprotease MMP-9 localizes to tumour-associated macrophages in human ovarian cancer but little is known of its regulation. Co-culture of human ovarian cancer cells (PEO-1) and a monocytic cell line (THP-1) led to production of 92-kDa proMMP-9. PEO-1-conditioned medium (CM) also stimulated THP-1 cells or isolated peripheral blood monocytes to produce proMMP-9. Expression of TIMP-1, however, remained unaffected. There was evidence that tumour necrosis factor alpha (TNF-a) was involved in tumour-stimulated monocytic proMMP-9 production. Antibody to TNF-ax inhibited proMMP-9 production, and synthesis of TNF-a mRNA and protein preceded proMMP-9 release. In addition, the synthetic matrix metalloprotease inhibitor (MMPI) BB-2116, which blocks TNF-a shedding, inhibited proMMP-9 release in the co-cultures and from CM-stimulated monocytic cells. Further experiments suggested that the stimulating factor present in CM was not TNF-ax, but acted synergistically with autocrine monocyte-derived TNF-ax to release monocytic proMMP-9. Thus, ovarian cancer cells can stimulate monocytic cells in vitro to make proMMP-9 without affecting the expression of its inhibitor TIMP-1. This induction is mediated via a soluble factor (provisionally named MMPSF) that requires synergistic action of autocrine or paracrine TNF-a.
Matrix metalloproteases (MMPs) are a family of structurally and functionally related endopeptidases. They have in common a zinc ion at the active site and are released as an inactive pro-form (zymogen). Proteolytic activation enables MMPs to degrade components of the extracellular matrix, such as collagens, fibronectin and laminin (for review Matrisian, 1990 Matrisian, , 1992 Woessner, 1991; Mauch et al, 1994; Murphy, 1995) . Of the MMPs cloned so far, the gelatinases MMP-2 and MMP-9 degrade in vitro native type IV collagen, the main constituent of the basement membrane. MMP activity is controlled at several levels. Gene expression is regulated by cytokines, such as tumour necrosis factor alpha (TNF-oc), transforming growth factor beta (TGF-,B) and interferons (for review Matrisian, 1990 Matrisian, , 1992 Woessner, 1991; Mauviel, 1993; Mauch et al, 1994; Murphy, 1995) , activation of MMPs can be triggered in vitro by proteases and other MMPs (Matrisian, 1990 (Matrisian, , 1992 Woessner, 1991; Mauch et al, 1994; Murphy, 1995; Sang et al, 1995) and, finally, their proteolytic activity is counterbalanced by tissue inhibitors of metalloproteases (TIMPs) (Matrisian, 1990 (Matrisian, , 1992 Woessner, 1991; Mauch et al, 1994; Murphy, 1995) .
MMPs play an important role in tissue remodelling during embryogenesis and wound healing (Matrisian, 1990 (Matrisian, , 1992 Bullen et al, 1995) . In addition, these enzymes contribute to the pathology of chronic diseases, such as osteo-and rheumatoid arthritis (Woessner, 1991; Woessner and Gunja Smith, 1991; Stetler Stevenson, 1996) , and malignancy (Liotta and Stetler Stevenson, 1991; Woessner, 1991; Stetler Stevenson, 1996) . Events such as angiogenesis, intra-and extravasation and migration of tumour or host immune cells have been associated with MMP activity (Liotta and Stetler Stevenson, 1991 ; Karelina et al, 1995) .
MMP-2 and -9 are present in biopsies of breast, bladder, ovarian, colorectal and prostate cancer and their levels seem to be related to tumour grade and invasion (Davies et al, 1993a and b; Hamdy et al, 1994; Naylor et al, 1994; Liabakk et al, 1996) . However, relatively little is known about the mechanisms leading to MMP expression in vivo. A recently published report describes the interaction of T cells and monocytes leading to MMP-9 release (Kiener et al, 1995) . A soluble factor, gp39, derived from T cells was found to be responsible for triggering MMP-9 production via monocytic CD40, the gp39-receptor.
The aim of our study was to investigate the interactions between human tumour cells and macrophages that lead to MMP-9 release. In previous work on biopsies of human ovarian cancer, the type IV gelatinases MMP-2 and MMP-9 were detected by zymography and their expression localized by in situ hybridization (Naylor et al, 1994) . MMP-2 mRNA was found exclusively in the tumour stroma, whereas MMP-9 expression was discrete and seen in both tumour and stromal areas. Immunohistochemical studies using an antibody to the macrophage marker CD68 showed a positive correlation with the pattern found for MMP-9, which suggested that tumour-associated macrophages (TAMs) may be the source of MMP-9 (Naylor et al, 1994) . TNF-ax expression, as assessed by in situ hybridization, was confined to epithelial tumour areas, whereas immunoreactive TNF-ox protein was found in both tumour and stromal areas. In this respect, the pattern of TNF-oc protein was similar to that found for infiltrating macrophages (Naylor et al, 1993) . These results suggested that TAMs could be the source of MMP-9 and that TNF-ox might play a role in its production (Naylor et al, 1993 (Naylor et al, , 1994 .
In this report, we describe a mechanism that leads to monocytic proMMP-9 but not to TIMP-1 production in the presence of ovarian cancer cells. We provide evidence that a tumour-derived soluble factor, tentatively named MMPSF (matrix metalloproteinase-stimulating factor) demonstrates synergy with autocrine or paracrine TNF-oc to stimulate MMP-9 release.
MATERIAL AND METHODS

Cell culture techniques
The human cell line PEO-1 was derived from ascites of a patient with a poorly differentiated adenocarcinoma before chemotherapy (Langdon et al, 1988) . The cell line was maintained in RPMI (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (FCS, Gibco) and 10 sg ml-' bovine insulin (Sigma, Poole, UK) and routinely passaged two to three times per week. The human monocytic cell line THP-1 was from ATCC (American Type Culture Collection, Rockville, IL, USA) and maintained at a cell concentration between 0.5 and lx 106cells ml-' in RPMI containing 10% FCS and 50 ltM beta-mercaptoethanol (Sigma). All cells were grown in Nunc tissue culture flasks and incubated in a humidified atmosphere at 37°C, 5% carbon dioxide.
Experimental cell culture conditions and preparation of conditioned medium PEO-1 cells were grown to near confluency, detached from the tissue culture flask with trypsin/versene (Gibco), resuspended in culture medium, pelleted (210 g, 5 min), washed up to three times in phosphate-buffered saline (PBS) and resuspended in FCS-free Aim V medium (Gibco). Similarly, THP-1 cells were pelleted (210g, 5 min) and resuspended in FCS-free Aim V. Cells were counted using a haemocytometer and, if not otherwise stated, the cell concentration adjusted to 1x106 cells ml-'. All experiments were set up in 24-or 96-well plates (Costar, Cambridge, MA, USA) and cell culture supematant harvested, unless stated otherwise, after an incubation period of 48 h. Supernatant was cleared of cells and cell debris by centrifugation at 14 000 r.p.m. in a microfuge before storage at -20°C or immediate use for zymography. For use as conditioned medium (CM), the supernatant was sterile filtered (Acrodisc 0.2 ,um, Gelman Sciences, Ann Arbor, MI, USA) before freeze-storage or use.
Isolation of peripheral blood monocytes
Peripheral blood (50 ml) was taken from healthy volunteers by venupuncture, mixed with 5 ml of 3.8% sodium citrate and centrifuged (20 min, 300 g) to obtain a cell pellet and platelet-rich plasma (PRP). PRP was centrifuged twice (2000g, 10 min) to remove the platelets (PPP, platelet-poor plasma) and stored on ice for later use. The cellular pellet was resuspended in 0.9% sodium chloride to 45 ml and erythrocytes precipitated with 5 ml of 6% Dextran T-500 (Pharmacia, Uppsala, Sweden). The lymphocyterich supernatant was transferred into a fresh tube, the cells pelleted by centrifugation (5 min, 200 g), washed three times in wash buffer (0.9% sodium chloride, 10% PPP) and resuspended in 8 ml of PPP. Two millilitres of cell suspension were under layered with 2 ml of 42% Percoll (Pharmacia) prepared with PPP. After centrifugation (O min, 300 g) the monocyte-rich interphase was harvested by aspiration, washed three times in wash buffer and resuspended in Aim V medium. The cells were seeded and after an incubation period of 1 h at 37°C washed three times with Aim V medium to select the monocytes by adhesion. To assess the purity of the preparation, an aliquot of cells was set to adhere on a Petri dish, washed in the same way as the cells used for the stimulation experiments, air dried, stained using the oc-naphthyl acetate esterase method (Yam et al, 1971 ) and counterstained with Meyers haematoxylin. The ratio of monocytes vs non-monocytes was determined by phase-contrast microscopy. In all experiments, purity of monocytes exceeded 90%.
Endotoxin assessment
All solutions and buffers (RPMI, PBS, AIM V, water, CM, etc.) used in cell culture were checked for endotoxin content using a kinetic turbidity assay (BioWhittaker, Reading, UK) or the endotoxin detection kit (0.50 EU ml-') purchased from Associates of Cape Cod (Woods Hole, MA, USA). Levels were found to be below 100 pg ml-'. Dose-response experiments of THP-1 cells to three types of endotoxin (E. coli 055:B5, 01 1 :B4 and Scalmonella minnesota) showed that levels of 100 pg ml-' or less did not stimulate MMP-9 release in a detectable manner (data not shown). To achieve levels of MMP-9 similar to those obtained in co-culture or CM experiments with THP-I (> fivefold background level), I ng ml-' or 726 TM Leber and FR Balkwill more of endotoxin was needed. Endotoxin levels present in FCS were assessed by Gibco and were found to be below 100 pg ml-'.
Zymogram analysis
Quantitative gelatinolytic zymography was performed according to an improved protocol described recently (Leber and Balkwill, 1997) . For gel to gel comparison, a standard of commercially available purified human proMMP-9 (TCS Biologicals, Botolph Claydon, UK) was loaded on each gel in duplicate. All samples were assessed in the linear range of the assay and the individual MMP-9 activity expressed in ng (MMP-9) per ,ul (supernatant). All values of MMP-9 activity were based on at least two independent experiments. The error bars reflect the standard deviation.
Spin column experiment
SpinColumns-30 (Clontech, Basingstoke, UK) were pre-spun twice for 3 min (4C, 1100 g) to remove the equilibration buffer. A 50-lt aliquot of sample was loaded on the spin column and spun for 5 min (4C, I 100 g). The flow-through was harvested and the volume adjusted to 55 ,tl with sterile PBS.
Immunoprecipitation of TNF-a
The monoclonal anti-TNF-oc antibody 6H 11 (kindly provided by Dr N-B Liabakk, Trondheim, Norway) was added to CM or control samples at a concentration of 5 ,ug ml-'. Samples were incubated for at least 1 h at 4°C on a rotor, then 40 gl of protein-G Sepharose (Sigma) added and samples incubated as before. To pellet the beads, samples were spun for 5 min at maximal speed in a microfuge and the supernatant carefully removed. To assess the MMP-9-inducing activity, the sample was added to THP-1 cells in a 1: 10 dilution. To check for the efficiency and specificity of TNFux precipitation, samples spiked with recombinant human TNF-ix at a concentration of 10 ng ml-' were prepared. Precipitation of TNF-oc and removal of the anti-TNF-ux antibody was complete and specific. The experiments have been repeated with a commercially available monoclonal anti-TNF-ox antibody (R&D Systems Europe, Abingdon, UK) and an unrelated antibody of the same antibody isotype.
RNA preparation and Northern blotting
Total RNA was isolated using TriReagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturers instructions, 10 Htg heated to 65°C for 5 min, resolved on a 1% denaturing formaldehyde-agarose gel and blotted onto a Hybond N+ membrane (Amersham, Slough, UK) by capillary transfer as described elsewhere (Balkwill, 1991) . RNA was UV cross-linked to the nylon membrane using a Stratalinker (Stratagene, Cambridge, UK) and blots prehybridized and hybridized as described (Balkwill, 1991) . cDNA probes for human TNF-ox, MMP-9 and 3-actin were radioactively labelled (32P-dCTP, Amersham) by random priming using the Prime-It or the RmTPrime-It labelling kit (Stratagene) according to the manufacturers instructions. After hybridization, blots were washed twice for 10 min at room temperature in 2 x standard saline citrate (SSC), 0.1I% sodium dodecyl sulphate (SDS), then incubated twice for 15 min in 0. 1% SSC, 0.1% SDS at 65°C and finally washed for 10 min in 2 x SSC at room temperature. For detection, blots were wrapped in Saranwrap (Dow Chemicals) and exposed at -70°C to BioMax X-ray film (Kodak) for 4 to 56 h.
Detection of TNF-a protein TNF-ox protein was detected using a WEHI-164 based bioassay (Espevik and Nissen Meyer, 1986) Role of TNF-a and MMPSF in MMP-9 production 727 
RESULTS
Co-culture of ovarian cancer cells and monocytic cells induces proMMP-9 independent from cell-cell contact
The co-culture system consisted of the ovarian cancer cell line PEO-1 and the monocytic cell line THP-1. As shown in Figure IA and B, supernatants generated when these cells were cultured alone contained low levels of the 92-kDa form of MMP-9 as measured by quantitative zymography. However, co-culture at a 1:1 ratio of tumour cells to monocytes led to strong production of proMMP-9 in supernatants. The identity of MMP-9 was confirmed by Western blotting (Figure lA, right panel) . Experiments showed that this 1:1 ratio was optimal (Figure 2 These results suggested that cell-cell contact was not required and that the monocytic cells were the source of proMMP-9. To test this further, we prepared conditioned medium (CM) from both PEO-1 and THP-1 cells. CM from THP-I cells did not enhance MMP-9 release from PEO-1 (data not shown), whereas PEO-1-derived CM induced proMMP-9 production by THP-1 (Figure 3 ). This induction was dose dependent and CM even at a 1:60 dilution CM had a clear proMMP-9-inducing effect on THP-1 cells. The identity of the protein induced by CM was confirmed as MMP-9 by Western blotting ( Figure IA, right panel) . Cell counting experiments showed that the cell numbers in CM-stimulated and control cultures were not significantly different (data not shown).
Peripheral blood monocytes (PBM) also produce proMMP-9 in response to CM Similar to the monocytic cell line THP-1, isolated peripheral blood monocytes released increased amounts of proMMP-9 in response to CM. However, to achieve the level of induction shown ( Figure  4 ), CM had to be concentrated 1 0-fold by ultrafiltration (NanoSpin Plus 10000 MWCO, Gelman Sciences, Ann Arbor, MI, USA).
TNF-a is involved in tumour-stimulated monocytic MMP-9 production Several lines of evidence suggested an involvement of the cytokine TNF-ac in monocytic production of MMP-9. First, recombinant TNFox induced proMMP-9 production by THP-I cells in a dose-dependent British Journal of Cancer (1998) manner. ProMMP-9 release was first detected at 0.3 ng ml-' TNF-a and reached its maximum at 10 ng ml-' TNF-a (data not shown). This finding is consistent with published results (Okada et al, 1990; Mauviel, 1993) . TNF-a (10 ng ml-') had, however, a minimal effect on MMP-9 release from PEO-1 cells (data not shown). Second, a monoclonal antibody that neutralized TNF-oc bioactivity inhibited MMP-9 release in co-cultures and also in CM-stimulated THP-1 cultures ( Figure 5A and B).
In accordance with published results (Gearing et al, 1994 (Gearing et al, , 1995 , we found that the matrix metalloprotease inhibitor BB-2 116 blocked shedding of TNF-ax from its membrane-spanning precursor after LPS stimulation of THP-I cells ( Figure 6A, IC50 300 nM) . This MMPI inhibited proMMP-9 production with a similar lC50 in coculture and in CM experiments ( Figure 6B and C, IC 0 590 nm and 860 nM). At the concentrations used in these experiments, BB-2 116 had no cytotoxic or cytostatic effects on THP-1 cells as assessed by cell counting experiments (data not shown) and phase-contrast microscopy. Further, BB-2116 did not interfere with zymogram analysis of proMMP-9 in the assessed range (< 300 mm, data not shown). The observation that an inhibitor of TNF-cx release also inhibited proMMP-9 release from monocytic cells when stimulated with CM led us to investigate a role for autocrine monocytic TNF-oc production in proMMP-9 release.
Analysis of MMP-9, TIMP-1 and TNF-a gene expression and protein MMP-9 and TNF-ac gene expression and protein production was studied in CM-stimulated and -unstimulated THP-I cells over 48 h of incubation. Using Northern analysis, MMP-9 mRNA was detected in both CM-stimulated and -unstimulated THP-1 cells at 6 h. In unstimulated cells, the signal remained weak and decreased to below the detection limit after 24 h of incubation ( Figure 7A ). In CMstimulated cells, however, MMP-9 expression was strongly induced, peaked at 14 h and remained strong until 48 h ( Figure 7A ). This finding is consistent with protein data obtained by zymography. First, proMMP-9 proteolytic activity was detected in the supernatant after 12 h, and levels seemed to increase steadily thereafter ( Figure 7B ).
Reprobing the above blot for TNF-a mRNA showed gene expression in both CM-stimulated and -unstimulated THP-1 cells with the same time course and level of expression ( Figure 7A ). TNF-ax mRNA was not detectable at the beginning of culture, peaked at 2 h and declined thereafter. TNF-a protein, as detected by bioassay or ELISA in three independent experiments, followed the pattern observed for mRNA. Maximal TNF-x protein was detected 5-8 h after stimulation (60 pg ml' and 21 pg ml-' as determined by bioassay and ELISA respectively). No TNF-a was detected at the beginning of the incubation period and the amounts decreased to the detection limit (ELISA, 15 pg ml-') or below (bioassay, 19 pg ml-'; data not shown) by 16 h.
Reprobing of the same blot for TIMP-1 mRNA showed no difference in TIMP-1 expression between unstimulated and CMstimulated THP-1 cells ( Figure 7A ). Reprobing of the blot with P-actin showed that loading was even ( Figure 7A ).
Thus, these experiments showed that THP-1 cells release low amounts of TNF-a even without stimulation with CM.
The proMMP-9-stimulating activity (MMPSF) present in CM is distinct from TNF-a The level of TNF-a in different batches of CM was measured by bioassay. This varied from 0 to 160 pg ml' without detectable British Journal of Cancer (1998) changes in the ability of CM to induce monocytic proMMP-9 (data not shown). Further, immunoprecipitation of potential TNF-a from CM had only a minor effect on its MMP-9-stimulating activity ( Figure 8A ). Controls showed that recombinant TNF-oc could be precipitated efficiently and the TNF-ax antibody 6H 11 was fully removed by protein-G sepharose precipitation. In addition, preparation of CM in the presence of 30 gM BB-2116, which blocks TNF-x shedding from the cell surface ( Figure 5A ), followed by removal of BB-2116 by gel filtration did not affect MMP-9 release when this CM was added to the monocytic cells ( Figure 8B ). Taken together, these results suggested that tumour cell-derived TNF-a did not play a major role in stimulation of monocytic MMP-9 production.
The tumour-derived soluble factor (MMPSF)
Our conclusion from the above experiments was that a tumour cell-derived soluble factor was synergistic with endogenous monocytic-produced TNF-ax to stimulate proMMP-9 production. The factor was heat sensitive; heating to 85°C for 30 min completely abolished its ability to induce MMP-9 (data not shown). Preliminary gel filtration experiments indicated a peak of activity with an apparent molecular mass of 89 kDa. This result was further evidence that MMPSF was distinct from TNF-ax, as the molecular mass of TNF-ax has been reported to be 45 kDa by gel filtration (Aggarwal et al, 1984) . A model summarizing our results is shown in Figure 9 .
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Our results further suggest a new mechanism of action of synthetic MMPIs in cancer. MMPIs were originally designed to reduce excessive MMP activity due to an imbalance of MMPs and their natural inhibitors (TIMPs). However, synthetic MMPIs also inhibit shedding of TNF-ox from its membrane spanning precursor (Gearing et al, 1994 (Gearing et al, , 1995 and of other cytokines: TGF-oc, FasL, C) Cancer Research Campaign 1998 IL-6 receptor, stem cell factor, M-CSF, TNF-oc receptors, Lselectin and thyrotropin receptor ectodomain (Crowe et al, 1995; Kayagaki et al, 1995; Mullberg et al, 1995; Bennett et al, 1996; Couet et al, 1996; Drummond and Gearing, 1996; Feehan et al, 1996) . Therefore, inhibition of release of cytokines that play a role in tumour development represents an alternative or additional mechanism of action of MMPIs. This option might be of particular importance if the cytokine has stimulatory activity on MMP gene expression, as is the case for TNF-ot. However, the IC50 values of synthetic MMPIs for MMPs are generally 10-to 100-fold lower than those that influence cytokine release (Chirivi et al, 1994; Gearing et al, 1994) . Hence, the effect might only be a secondary one to MMP inhibition. However, because of the broad activities of cytokines and their potency, even small changes might contribute to the observations made in animal models of human cancer (Talbot and Brown, 1996) or in current clinical trials.
In this study, we established a simple in vitro system that allowed us to analyse the mechanisms leading to monocytic MMP-9 production. Our in vitro findings were in keeping with the observations made on biopsy material of human ovarian cancer. Further studies are required to fully characterize MMPSF and to determine the biological role of the 92-kDa pro-form of MMP-9.
